Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study)
Por:
Hernández-García M, Molina-Barceló A, Vanaclocha-Espi M, Zurriaga Ó, Pérez-Gómez B, Aragonés N, Amiano P, Altzibar JM, Castaño-Vinyals G, Sala M, Ederra M, Martín V, Gómez-Acebo I, Vidal C, Tardón A, Marcos-Gragera R, Pollán M, Kogevinas M and Salas D
Publicada:
1 ene 2022
Ahead of Print:
1 nov 2021
Resumen:
Purpose The variation in breast cancer (BC)-risk factor associations between screen-detected (SD) and non-screen-detected (NSD) tumors has been poorly studied, despite the interest of this aspect in risk assessment and prevention. This study analyzes the differences in breast cancer-risk factor associations according to detection method and tumor phenotype in Spanish women aged between 50 and 69. Methods We examined 900 BC cases and 896 controls aged between 50 and 69, recruited in the multicase-control MCC-Spain study. With regard to the cases, 460 were detected by screening mammography, whereas 144 were diagnosed by other means. By tumor phenotype, 591 were HR+, 153 were HER2+, and 58 were TN. Lifestyle, reproductive factors, family history of BC, and tumor characteristics were analyzed. Logistic regression models were used to compare cases vs. controls and SD vs. NSD cases. Multinomial regression models (controls used as a reference) were adjusted for case analysis according to phenotype and detection method. Results TN was associated with a lower risk of SD BC (OR 0.30 IC 0.10-0.89), as were intermediate (OR 0.18 IC 0.07-0.44) and advanced stages at diagnosis (OR 0.11 IC 0.03-0.34). Nulliparity in postmenopausal women and age at menopause were related to an increased risk of SD BC (OR 1.60 IC 1.08-2.36; OR 1.48 IC 1.09-2.00, respectively). Nulliparity in postmenopausal women was associated with a higher risk of HR+ (OR 1.66 IC 1.15-2.40). Age at menopause was related to a greater risk of HR+ (OR 1.60 IC 1.22-2.11) and HER2+ (OR 1.59 IC 1.03-2.45) tumors. Conclusion Reproductive risk factors are associated with SD BC, as are HR+ tumors. Differences in BC-risk factor associations according to detection method may be related to prevailing phenotypes among categories.
Filiaciones:
:
Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain
:
Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain.
:
Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain
:
Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine Department, University of Valencia, Avda. Vicent Andrés Estellés, s/n, 46100, Burjassot, Valencia, Spain
Joint Research Unit on Rare Diseases, FISABIO-UVEG, Avda. Catalunya 21, 46020, Valencia, Spain
Directorate General of Public Health, Avda. Catalunya 21, 46020, Valencia, Spain
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Pérez-Gómez B:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Department of Epidemiology of Chronic Diseases, National Center of Epidemiology, Carlos III Health Institute (ISCIII), Avda. Monforte de Lemos 5, 28029, Madrid, Spain
Aragonés N:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Epidemiology Section, Public Health Division, Department of Health of Madrid, C/San Martín de Porres, 6, 28035, Madrid, Spain
Amiano P:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, Doctor Begiristain, s/n, 20014, San Sebastián, Spain
Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 2013, San Sebastian, Spain
Altzibar JM:
Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, Doctor Begiristain, s/n, 20014, San Sebastián, Spain
ISGlobal, Barcelona Institute for Global Health, Doctor Aiguader 88, 08003, Barcelona, Spain
Castaño-Vinyals G:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
ISGlobal, Barcelona Institute for Global Health, Doctor Aiguader 88, 08003, Barcelona, Spain
IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain
Universitat Pompeu Fabra (UPF), Plaça de la Mercè, 10-12, 08002, Barcelona, Spain
Sala M:
IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain
Ederra M:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Navarra Public Health Institute, C/ Leyre, 15, 31003, Navarra, Spain
IdiSNA, Navarra Institute for Health Research, C/Irunlarrea, 3, 31008, Pamplona, Spain
Martín V:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
The Research Group in Gene - Environment and Health Interactions (GIIGAS), Biomedicine Institute (IBIOMED), University of León, Vegazana Campus, s/n, 24071, León, Spain
Gómez-Acebo I:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Cantabria University- IDIVAL, C/Cardenal Herrera Oria, s/n, Santander, 39011, Cantabria, Spain
Vidal C:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Cancer Screening Unit, Catalan Institute of Oncology, Duran I Reynals Hospital, Avda. de La Gran Via de L'Hospitalet, 199-203, L'Hospitalet de Llobregat, 08908, Barcelona, Spain
Early Detection of Cancer Research Group, EPIBELL Program, Bellvitge Biomedical Research Institute, Avda. de La Granvia de L'Hospitalet, 199, L'Hospitalet de Llobregat, 08908, Barcelona, Spain
Tardón A:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Oncology Institute (IUOPA), University of Oviedo, Edificio Santiago Gascón, Campus El Cristo B, 33006, Oviedo, Spain
Marcos-Gragera R:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology. Sant Ponç, Avda de França, 0, 17007, Girona, Spain
Descriptive Epidemiology, Genetics and Cancer Prevention Group, [Girona Biomedical Research Institute] IDIBGI, C/ del Dr. Castany, s/n, Salt, 17190, Girona, Spain
Pollán M:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
National Center of Epidemiology Directorate, Carlos III Health Institute (ISCIII), Avda. Monforte de Lemos 5, 28029, Madrid, Spain
Kogevinas M:
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
ISGlobal, Barcelona Institute for Global Health, Doctor Aiguader 88, 08003, Barcelona, Spain
IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain
Universitat Pompeu Fabra (UPF), Plaça de la Mercè, 10-12, 08002, Barcelona, Spain
:
Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain
Directorate General of Public Health, Avda. Catalunya 21, 46020, Valencia, Spain
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
hybrid, Green Published
|